21 July 2021
Bio Products Laboratory (“BPL”) issues an update on its financial results and operational highlights for the six months ending 30 June 2021. BPL is a vertically integrated manufacturer of plasma-derived medicinal products headquartered in Elstree, UK. BPL consists of two divisions, BPL Plasma, based in Texas, which collects plasma from 26 centres across the US, and BPL Therapeutics in the UK, which manufactures high-quality products.
1st Half Highlights:
David Gao, BPL’s Vice Chairman & Chief Executive Officer, commented:
“I am delighted with our performance in the first half of the year, and I would like to thank all of our employees for the part they play in helping BPL deliver on our long-term strategic goals.
Although Covid-19 continues to affect our business and the global economy, as we enter the second half of the year, I am confident that we are well-positioned to continue delivering strong growth in the long term, underpinned by the strength of our business, increasing demand for our products and the growth of the global plasma market.”
Michael Mensa, BPL’s President and Chief Financial Officer, said:
“I am very pleased with our better-than-expected financial performance for BPL in the first half of this year, and the momentum we have as a company as we look forward. The continued success of our products globally and our execution focus in delivering for our customers are key to our success. It is promising to see that US plasma collections are now showing signs of recovery from their Covid-19 depressed levels, as we enter the second half of the year.”
Donna Mitchell, BPL Communications Manager: Donna.Mitchell@bpl.co.uk